A Clinic-Based Program in India Helped Heart and Stroke Patients Stick to Treatment — Here's What Changed

If you've ever watched a family member leave the cardiologist's office with a fistful of prescriptions, only to quietly stop taking them a few months later, you've seen a version of the problem this study tackles. Across the world, but especially in lower- and middle-income countries, people who survive a heart attack, stroke, or heart failure diagnosis often don't get the follow-up care that could prevent the next one. A new feasibility trial published in PLOS Medicine tested whether a bundle of relatively low-tech interventions could close that gap in Indian outpatient clinics.

The Problem Behind the Numbers

Cardiovascular disease remains the world's leading contributor to death globally, and working-age adults in places like India bear a heavy share of that burden. Guidelines for managing heart disease, stroke, and heart failure are well established, but actually delivering that care consistently — getting patients on the right combination of medications, making sure they understand their condition, and following up over time — is a different challenge. Earlier international research, including the Prospective Urban Rural Epidemiology study, had already flagged how large this implementation gap can be, even years after a cardiovascular event.

What the Researchers Tried

A team led by researchers at the Centre for Chronic Disease Control and collaborating institutions designed something called C-QIP, short for a Collaborative Quality Improvement strategy. Rather than testing a single new drug or device, they combined five supports: software that nudges doctors toward guideline-based prescribing, a non-physician coordinator who helps patients navigate their care, structured patient education, text-message reminders, and regular feedback to clinical teams based on audits of their own performance.

The trial enrolled 410 adults with ischemic heart disease, ischemic stroke, or heart failure from four hospitals — a mix of public and private — in India. Participants were randomly assigned to receive either the full C-QIP package or usual care, and the research team followed them for a median of about 15 months.

Did People Actually Stick With It?

Before asking whether the program worked, the researchers needed to know whether it was even realistic to deliver and whether patients would stay engaged. On that front, the results were encouraging: more than 93% of participants in the C-QIP group and over 91% in the usual-care group remained in the study through its end. Among those receiving the intervention, fidelity was high too. Nearly 94% of participants were still receiving lifestyle counseling by the final visit, suggesting the program held together operationally rather than fading out over time.

Where the Program Appeared to Make a Difference

The more clinically interesting findings involve how many patients ended up on the recommended combination of preventive medications, what the researchers call guideline-directed medical therapy. Among people with ischemic heart disease, 58.3% of the C-QIP group reached this benchmark compared with 32.4% in usual care. For ischemic stroke, the gap was even larger — 76.7% versus 31.8%. Statistically, these differences translated into a 45% and more than two-fold relative increase, respectively, in reaching guideline-based treatment. Heart failure patients didn't show a significant improvement in this measure, though, a reminder that the same strategy doesn't necessarily work equally well across different conditions.

Self-reported adherence told a similar story. People in the C-QIP group were more likely to say they were taking their medications as prescribed, following dietary recommendations, and staying physically active, with the largest difference showing up in physical activity levels (91.4% versus 70.4%).

Limits of a Feasibility Trial

This was a feasibility trial, designed primarily to see whether the program could be implemented and accepted, not a large-scale trial powered to detect changes in heart attacks, strokes, or deaths. Patients were randomized as individuals within the same clinics rather than by clinic site, which raises the possibility that usual-care patients picked up some benefit simply by being treated alongside C-QIP patients. That contamination effect could blur the true difference between groups. The authors note this limitation themselves. Anyone managing heart disease, stroke recovery, or heart failure should treat these findings as context for a conversation with their own doctor, not a substitute for one, since the right mix of medications and monitoring still depends on individual circumstances.

Next Step: Clinic-Wide Trials Measuring Heart Attacks and Strokes

The authors call for larger studies using cluster-randomized designs, where entire clinics rather than individual patients are assigned to one strategy or the other, to test whether C-QIP reduces heart attacks, strokes, and deaths. In this trial, the five components were delivered together in routine outpatient care at four hospitals, and patients kept using them through about 15 months of follow-up.

Source: PLOS Medicine, DOI: 10.1371/journal.pmed.1004932, based on the C-QIP randomized feasibility trial by Singh et al.